Related content

Bayesian Calibration of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Carbaryl Cholinesterase Inhibition

By Nong Andy   Tan Yu-Mei   Krolski Michael   Wang Jiansuo   Lunchick Curt   Conolly Rory   Clewell Harvey  

Journal of Toxicology and Environmental Health, Vol. 71, Iss. 20, 2008-01 ,pp. : 1363-1381

Taylor & Francis Ltd

Access to resources Recommend Favorite

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modelling of the Reversal of Buprenorphine-Induced Respiratory Depression by Naloxone: A Study in Healthy Volunteers

By Yassen Ashraf  

Clinical Pharmacokinetics, Vol. 46, Iss. 11, 2007-01 ,pp. : 965-980

Adis International

Access to resources Recommend Favorite

An integrated pharmacokinetic–pharmacodynamic model for an Aurora kinase inhibitor

By Kamei Hiroko   Jackson Robert   Zheleva Daniella   Davidson Fordyce  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 37, Iss. 4, 2010-08 ,pp. : 407-434

Springer Publishing Company

Access to resources Recommend Favorite

A Pharmacokinetic–Pharmacodynamic Model of Chemotherapy of Human Immunodeficiency Virus Infection that Relates Development of Drug Resistance to Treatment Intensity

By Jackson Robert C.  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 25, Iss. 6, 1997-12 ,pp. : 713-730

Springer Publishing Company

Access to resources Recommend Favorite

Role of Mechanistically-Based Pharmacokinetic/Pharmacodynamic Models in Drug Development: A Case Study of a Therapeutic Protein

By Marshall Scott  

Clinical Pharmacokinetics, Vol. 45, Iss. 2, 2006-01 ,pp. : 177-197

Adis International

Access to resources Recommend Favorite